Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Navinci logo — Illuminating function is spatial proteomics

Navinci

Illuminating function is spatial proteomics

Founded 2004 Sweden Sweden 31 employees Series A Total: $90.00M Biotechnology, Health Care

General Information

Company Name Navinci
Founded Year 2004
Location Sweden Sweden
Employees 31
Industries Biotechnology, Health Care
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Navinci. To contact Navinci, visit navinci.se.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Navinci compare?

A PDF of Navinci and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Navinci soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Navinci

Navinci is a Swedish biotech company founded in 2004, which specializes in developing innovative solutions for the study of protein interactions. The company's flagship product, Naveni Proximity Ligation Technology, is at the forefront of innovation in spatial proteomics, enabling sensitive and specific detection and quantification of protein interactions and post-translational modifications. With a strong legacy in in situ proximity ligation assay technology, Navinci has established itself as a center of excellence in this field. The company's latest focus is on target-specific kits within immuno-oncology, designed to help researchers visualize interactions such as PD1/PD-L1 and elucidate the role that interactions, rather than individual proteins, play in the development of cancer. In July 2022, Navinci secured a kr90.00M Series A investment from notable investors including Segulah Medical Acceleration, Beijer Ventures, Nxt2b, and Landegren Gene Technology. This investment signifies confidence in Navinci's potential to provide reliable and innovative tools for visualizing and interpreting protein interplay, thus pushing forward the understanding of cell biology and bringing precision to spatial proteomics in the fields of biotechnology and health care.

Business keywords: Spatial Proteomics, Proximity Ligation, In Situ Assays, Protein Interactions, Post-Translational Modifications, Immuno-Oncology, Biomarker Detection, Cancer Research, Cell Biology, Protein Quantification, Diagnostic Technology, Biotech Innovation, Protein Visualization, Biological Interactions, Precision Medicine

Services & Products

In situ proximity ligation assay-based solutions for protein interaction and modification analysis

Target Customers

Biomedical researchers pharmaceutical companies academic institutions CROs

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A kr90.00M 4
Segulah Medical Acceleration Beijer Ventures
Segulah Medical Acceleration, Beijer Ventures +2
12 Jul 2022

Navinci Alternatives & Competitors

View All Alternatives
Navinci vs
Oxford BioTherapeutics
Oxford BioTherapeutics United Kingdom

Redefining the cancer-immune synapse for novel immune checkpoint mechanisms

66 employees
Biotechnology, Health Care
Compare Navinci vs Oxford BioTherapeutics
Navinci vs
2seventy bio
2seventy bio United States

It’s about time we think smarter and faster than cancer.

Acquired
122 employees
Biotechnology, Health Care
Compare Navinci vs 2seventy bio
Navinci vs
Lunaphore (a Bio-Techne brand)
Lunaphore (a Bio-Techne brand) Switzerland

Lunaphore is now under the portfolio brand: Bio-Techne Spatial. Follow our new page for updates.

Series D
84 employees
Biotechnology, Health Care
View all alternatives

FAQ About Navinci

Illuminating function is spatial proteomics
Navinci was founded in 2004.
Navinci is headquartered in Sweden.
Navinci operates in Biotechnology and Health Care. Its work centres on Spatial Proteomics, Proximity Ligation, In Situ Assays and Protein Interactions. Its customers include Biomedical researchers, pharmaceutical companies and academic institutions.
Navinci has approximately 31 employees.
Navinci has completed 1 funding round, raising a total of $90.00M. The latest funding stage is Series A.
Navinci offers: In situ proximity ligation assay-based solutions for protein interaction and modification analysis.
Top alternatives and competitors to Navinci include Oxford BioTherapeutics, 2seventy bio, Lunaphore (a Bio-Techne brand), Farcast Biosciences, Imugene Limited. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Navinci and Oxford BioTherapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Navinci, https://bouncewatch.com/company/navinci-diagnostics, updated 25 March 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes